Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Cancer ◽  
2020 ◽  
Author(s):  
Christine M. Heske ◽  
Yueh‐Yun Chi ◽  
Rajkumar Venkatramani ◽  
Minjie Li ◽  
Michael A. Arnold ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Survival Outcomes ◽  
Oncology Group

Contributions from surgeons to clinical trials and research on the management of soft tissue sarcoma

1998 ◽  
Vol 5 (5) ◽  
pp. 437-441 ◽  
Author(s):  
Peter J. Allen ◽  
Alexander Stojadinovic ◽  
Craig D. Shriver ◽  
David P. Jaques
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma

scholarly journals Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe

2019 ◽  
Vol 30 ◽  
pp. v693
Author(s):  
V. Ostafiichuk ◽  
S.I. Korovin ◽  
M.N. Kukushkina
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Eastern Europe

scholarly journals Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology

2017 ◽  
Vol 16 (10) ◽  
pp. 2555-2562 ◽  
Author(s):  
Dušica J Popović ◽  
Mihalj Poša ◽  
Kosta J Popović ◽  
Jovanka Kolarović ◽  
Jovan K. Popović ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Glioblastoma Multiforme ◽  
Cell Growth ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Acute Myeloid Leukaemia ◽  
Preclinical Studies ◽  
Cancer Cell Growth ◽  
Tropical Areas ◽  
Acute Myeloid

Although clinical trials have not been completed, it has already been confirmed that mebendazole, a well-known anti-parasitic drug widely used in the tropical areas, inhibits cancer cell growth. Preclinical studies show that mebendazole notably impedes the growth of malignant and metastatic tumors such as osteosarcoma and soft tissue sarcoma, melanoma, carcinoma (lung, colorectal, breast, ovarian, hepatocellular and adrenocortical), acute myeloid leukaemia, glioblastoma multiforme and  meduloblastoma. Mebendazole can induce the depolymerization of microtubules in neoplasms and newly formed vasculature, stopping tumor growth and neoangiogenesis, along with other proposed mechanisms of action.Keywords: Anthelmintic, Mebendazole, Cancer treatment, Antimicrotubullar effect, Antineoangiogenesis

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1987 ◽  
Vol 5 (6) ◽  
pp. 851-861 ◽  
Author(s):  
L H Baker ◽  
J Frank ◽  
G Fine ◽  
S P Balcerzak ◽  
R L Stephens ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Actinomycin D ◽  
Malignant Tumors ◽  
Soft Tissue Sarcomas ◽  
Comparative Trial ◽  
Phase Iii ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Significant Difference

The term soft tissue sarcoma refers to a large variety of malignant tumors arising in extraskeletal connective tissues that connect, support, and surround discrete anatomic structures. All visceral organs also contain a connective stroma that can undergo malignant transformation. Because of the histological similarities of this group of tumors and their relative rarity, treatment prescriptions for patients that have disseminated disease are most often uniform. In this study, we asked the question whether adding a third drug (cyclophosphamide or actinomycin D) to Adriamycin (Adr [Adria Laboratories, Columbus, OH])-(3,3-dimethyl-1-triazeno)- imidazole-4-carboxamide (DTIC) would improve the response rate and/or survival. A unique feature of this cooperative group clinical trial was the mandatory pathology review of the histological material. All patients of the Southwest Oncology Group between June 1, 1976, and November 17, 1979, who had a biopsy-confirmed diagnosis of a soft tissue sarcoma with convincing clinical or biopsy-documented evidence of metastatic disease were eligible for the study. Patients were randomized to receive (1) Adr, 60 mg/m2 intravenously, day 1, and DTIC, 250 mg/m2 every 3 weeks (104 patients); (2) Adr and DTIC as in (1) and cyclophosphamide, 500 mg/m2, day 1 (112 patients); or (3) Adr and DTIC as in (1) and actinomycin D, 1.2 mg/m2, day 1, (119 patients). There was no statistically significant difference in response rates (33%, 34%, and 24%) (P = .25). Median durations of response were 31 weeks in the Adr-DTIC arm, 26 weeks in the cyclophosphamide-DTIC-Adr arm, and 23 weeks in the Adr-DTIC-Actinomycin D arm (P = .78). Median durations of survival were 37, 42, and 50 weeks, respectively. Again, no statistically significant differences were observed (P = .59). Toxicities from each of these treatment arms were formidable and were equivalent. Prognostic factor analysis showed a prognosis based on bone marrow reserve, sex, and pathology subtype favorable to patients.

Sign in / Sign up

Export Citation Format

Share Document